EffRx Pharmaceuticals announces the launch of Alkindi® as replacement therapy for pediatric adrenal insufficiency in Switzerland

FREIENBACH, Switzerland – EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announces the launch of Alkindi® (hydrocortisone capsules for oral use) in Switzerland as replacement therapy for adrenal insufficiency in infants, children and adolescents (from birth to <18 years old). Alkindi® is the first approved pediatric-specific

Learn More

EffRx Attending the 9th I-DSD Symposium 2022 in Bern, Switzerland, University Hospital Bern from 14-16th July 2022

The International Symposium on the Differences & Disorders of Sex Development I-DSD has been very successful in attracting a rapidly expanding multidisciplinary group of experts, eager to discuss the latest advances in the field and have laid the foundation for fruitful international collaborations. In 2021, the I-DSD/I-CAH/I-TS has a network that reaches 260 centers in 63

Learn More

EffRx Pharmaceuticals Signs Exclusive License Agreement with Diurnal for the Registration and Commercialization of Efmody® in Switzerland

FREIENBACH, Switzerland –-BUSINESS WIRE–-  EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced it has recently entered into an exclusive license agreement with Diurnal Group plc, for the registration and commercialization of Efmody® as a treatment for congenital adrenal hyperplasia (CAH) in Switzerland. Under the terms

Learn More

EffRx Supports the 15th Annual Rare Disease Day on 28. February 2022

Rare Disease Day is the globally-coordinated movement on rare diseases, working towards equity in social opportunity, healthcare, and access to diagnosis and therapies for people living with a rare disease. Since its creation in 2008, Rare Disease Day has played a critical part in building an international rare disease community that is multi-disease, global, and

Learn More

EffRx Obtains Swiss Marketing Authorization for Alkindi® for Paediatric Adrenocortical Insufficiency

FREIENBACH, Switzerland –-BUSINESSWIRE— EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced that Swissmedic has approved Alkindi® for the treatment of paediatric adrenocortical insufficiency (AI). Alkindi®, developed by Diurnal Group plc, is the first preparation of hydrocortisone specifically designed for use in children suffering from paediatric adrenocortical

Learn More

EffRx Obtains Swiss Marketing Authorization for Bronchitol® in Cystic Fibrosis

FREIENBACH, Switzerland –(BUSINESS WIRE)–EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced that Swissmedic has approved Bronchitol® (inhaled mannitol) for the treatment of cystic fibrosis (CF) in adults and in children aged 6 years and above as add‐on to other medicines. Bronchitol® is a precision spray‐dried

Learn More

EffRx Announces the Appointment of Göran Linder to of the Board of Directors

Freienbach, July 21, 2021 — EffRx Pharmaceuticals SA, a commercial-stage pharmaceutical company focused on the late-stage development and commercialization of prescription medications for niche and orphan indications, today announced the appointment of Göran Linder to its Board of Directors. “As the representative of EffRx’s major shareholder, I actively promoted the turn-around that the company and

Learn More

EffRx Pharmaceuticals | EffRx